NCT05283161View on ClinicalTrials.gov

CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann)

PHASE2/PHASE3UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

August 20, 2022

Study Completion Date

November 20, 2022

Conditions

Fibromyalgia

Interventions

DRUG

cannabidiol and tetrahydrocannabinol

CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.

DRUG

Placebo

The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking.